Provider Briefing: Aminosyn 3.5% M, Sulfite Free Shortage in 2026

The ongoing shortage of amino acid injection products continues to affect parenteral nutrition prescribing across hospital and home infusion settings. This briefing provides prescribers, pharmacists, and nutrition support professionals with the current status of Aminosyn 3.5% M, Sulfite Free availability, practical guidance for managing patients during the shortage, and resources to streamline care.

Shortage Timeline and Background

Amino acid injection products have experienced recurring shortages since at least 2014. The current shortage cycle has been driven by several converging factors:

• 2023: ICU Medical issued a voluntary nationwide recall of Aminosyn II 15% due to particulate matter, further constraining the amino acid product market and creating downstream supply pressure on other Aminosyn formulations including the 3.5% M product.
• Late 2024: The broader IV fluid supply chain crisis — triggered by hurricane damage to manufacturing facilities — exacerbated shortages across all sterile injectable products, including amino acid solutions.
• 2025: The American Society for Parenteral and Enteral Nutrition (ASPEN) published updated Parenteral Nutrition Product Shortage Recommendations specifically addressing amino acid product management strategies.
• 2026: ASHP continues to list amino acid products in active shortage. Supply remains intermittent across manufacturers.

Prescribing Implications

The limited availability of Aminosyn 3.5% M, Sulfite Free has several important clinical implications:

Route of Administration Considerations

Aminosyn 3.5% M, Sulfite Free is one of the few amino acid products suitable for peripheral vein administration when combined with 5% to 10% dextrose, due to its relatively low osmolarity (421 mOsmol/L). Most alternative amino acid products (Travasol 10%, Clinisol 15%, FreAmine III 10%, Aminosyn II in higher concentrations) require central venous access.

For patients who are currently receiving peripheral parenteral nutrition and whose Aminosyn 3.5% M supply is interrupted, prescribers will need to evaluate whether:

• Central line placement is clinically appropriate and feasible
• The patient's nutritional needs can be temporarily met through lower-protein peripheral regimens
• Transition to enteral nutrition is possible, even partially

Electrolyte Management

Aminosyn 3.5% M includes preset maintenance electrolytes (Na+ 40 mEq/L, K+ 13 mEq/L, Mg++ 3 mEq/L, phosphorus 3.5 mM/L, Cl- 40 mEq/L, acetate 65 mEq/L). When switching to products without preset electrolytes, pharmacy compounding must account for individual electrolyte supplementation, which increases preparation complexity and potential for errors.

Dose Optimization

During shortage periods, ASPEN recommends reviewing protein goals and considering whether patients can safely receive reduced amino acid doses temporarily. For non-critically ill adult patients, protein goals of 1.0 to 1.2 g/kg/day may be sufficient, rather than the higher targets used in critical illness (1.2 to 2.0 g/kg/day).

Current Availability Picture

As of early 2026, the availability landscape for amino acid products includes:

• Aminosyn 3.5% M, Sulfite Free (Pfizer/ICU Medical): Intermittent supply; allocations vary by distributor
• Aminosyn II Sulfite-Free (various concentrations): Limited availability in some concentrations
• Travasol 10% (Baxter): Generally more available than Aminosyn products, though subject to its own supply constraints
• Clinisol 15% Sulfite-Free (Baxter): Available in limited quantities; commonly used as a substitute
• FreAmine III 10%: Limited availability
• Clinimix/Clinimix E (Baxter): Premixed amino acid/dextrose combinations may offer an alternative for appropriate patients

All amino acid products are considered therapeutically equivalent on a gram-for-gram basis, though they differ in amino acid profiles, electrolyte content, and concentration. The substitution algorithm should prioritize products that match the patient's clinical needs and available vascular access.

Cost and Access Considerations

The cash price for Aminosyn 3.5% M, Sulfite Free is approximately $72 per 6,000 mL (six 1,000 mL bags). However, total parenteral nutrition therapy costs — including dextrose, lipid emulsions, vitamins, trace elements, supplies, pump rental, and nursing — typically range from $200 to $500+ per day for home infusion patients.

Insurance coverage for parenteral nutrition is typically under the medical benefit. Medicare covers home PN under Part B when patients meet specific criteria (permanent or long-term intestinal failure). Prior authorization is commonly required. When substituting products due to shortage, coverage should generally transfer, but providers may need to submit documentation explaining the clinical rationale for the product change.

Tools and Resources for Providers

Several resources can help you manage patients during the amino acid shortage:

• Medfinder for Providers: Search for available amino acid products and connect with pharmacies that have stock. A useful tool for quickly identifying supply sources.
• ASHP Drug Shortage Database: Monitor the current shortage status of amino acid products, including specific NDCs, manufacturer updates, and estimated resupply dates.
• ASPEN 2025 PN Product Shortage Recommendations: Clinical guidance for managing amino acid shortages, including triage protocols, dose optimization strategies, and substitution algorithms.
• Hospital Nutrition Support Team: Engage your institution's nutrition support team (or consult service) for patient-specific recommendations during product transitions.

Looking Ahead

The amino acid product shortage is unlikely to resolve quickly. The fundamental challenge — a very small number of manufacturers producing complex sterile injectable products — will persist until new manufacturing capacity comes online or demand patterns shift.

In the interim, providers should:

• Maintain institutional protocols for amino acid product substitution
• Educate patients on the possibility of product changes and what to expect
• Develop relationships with multiple home infusion pharmacies to diversify supply sources
• Monitor ASHP and ASPEN for ongoing updates
• Consider proactive enteral nutrition advancement when clinically appropriate to reduce PN dependence

Final Thoughts

Managing parenteral nutrition during an amino acid shortage requires clinical flexibility, proactive communication, and strong collaboration between prescribers, pharmacists, and nutrition support teams. While the shortage of Aminosyn 3.5% M, Sulfite Free is expected to continue through 2026, the availability of multiple therapeutic alternatives means that most patients can continue to receive adequate nutritional support.

For patient-facing resources you can share, see:

• Aminosyn 3.5% M, Sulfite Free Shortage Update for Patients
• Alternatives to Aminosyn 3.5% M, Sulfite Free
• How to Find Aminosyn 3.5% M, Sulfite Free in Stock

Use Medfinder for Providers to quickly locate available supply for your patients.